🚀 Exciting Advancement in Point-of-Care Diagnostics for IBD 🌟 Just read this incredible research work by Fei and the talented team at UNSW! This innovative study showcases the development of a portable CRISPR/Cas12a-based biosensor that allows for rapid, sensitive, and specific detection of calprotectin in mucosal samples. The portable assay demonstrated exceptional performance in a preclinical rodent model of ulcerative colitis, providing a much-needed solution for POCT. 🧬💡 ✅ A detection range of 1 to 10,000 ng/ml. ✅ Validated with mucosal samples to achieve accurate detection in a non-invasive manner. ✅ Potential to revolutionize clinical IBD diagnostics by providing rapid and precise results. This breakthrough not only brings us closer to more accessible diagnostics for chronic diseases like IBD but also highlights the power of combining cutting-edge CRISPR technology with innovative biosensing strategies. 🔥💪 #IBD #UlcerativeColitis #Diagnostics #CRISPR #MedicalResearch #PointofCare #Innovation
Congratulations on your publication FEI DENG
Strategic Communications Advisor & Fractional CCO | Empowering Companies + HNWIs + Execs: Driving Awareness, Expansion, and Impact | Aspiring Intelligence Group Operator📍D.C. / SLC
2moPioneering research propels POCT vision for IBD.